Human Pathology
Volume 38, Issue 9 , Pages 1305-1309.e4 , September 2007

Recommendations for the reporting of prostate carcinoma

  • Jonathan I. Epstein, MD

      Affiliations

    • Departments of Pathology, Urology, and Oncology, The Johns Hopkins Medical Institutions, Baltimore, MD 21231, USA
    • Corresponding Author InformationCorresponding author.
    • ,
  • John Srigley, MD

      Affiliations

    • Department of Pathology, The Credit Valley Hospital, Mississauga, Ontario, Canada L5M2N1
    • ,
  • David Grignon, MD

      Affiliations

    • Department of Pathology and Laboratory Medicine, Indiana University, Indianapolis, IN 46202, USA
    • ,
  • Peter Humphrey, MD, PhD

      Affiliations

    • Department of Pathology and Immunology, Washington University School of Medicine, St. Louis, MO 63110, USA
    • ,
  • on behalf of the Association of Directors of Anatomic and Surgical Pathology

Received 15 May 2007 ,Accepted 16 May 2007.

References 

  1. Amin M, Boccon-Gibod L, Egevad L, et al. Prognostic and predictive factors and reporting of prostate carcinoma in prostate needle biopsy specimens. (2004 WHO-sponsored International Consultation Consensus). Scand J Urol Nephrol. 2004;39(Suppl 216):20–33
  2. In:  Eble JN,  Sauter G,  Epstein JI,  Sesterhenn IA editor. Pathology and genetics of tumours of the urinary system and male genital organs. Lyon: IARC Press; 2004;p. PB 162–PB 192
  3. Epstein JI. The evaluation of radical prostatectomy specimens: therapeutic and prognostic implications. Pathol Annu. 1991;26:159–210
  4. Epstein JI, Amin M, Boccon-Gibod L, et al. Prognostic factors and reporting of prostate carcinoma in radical prostatectomy and pelvic lymphadenectomy specimens. (2004 WHO-sponsored International Consultation Consensus). Scand J Urol Nephrol. 2004;39(Suppl 216):34–63
  5. Grignon DJ, Sakr WA. Pathologic staging of prostate carcinoma: what are the issues?. Cancer. 1996;78:337–340
  6. May F, Hartung R, Breul J. The ability of the American Joint Committee on Cancer Staging system to predict progression-free survival after radical prostatectomy. BJU Int. 2001;88:702–777
  7. Ohori M, Kattan M, Scardino PT, Wheeler TM. Radical prostatectomy for carcinoma of the prostate. Mod Pathol. 2004;17:349–359
  8. Young RH, Srigley JR, Amin MB, Ulbright TM, Cubilla A. Tumors of the prostate gland, seminal vesicle, male urethra and penis. In:  Rosai J editors. Atlas of Tumor Pathology. Series 3. Washington (DC): Armed Forces Institute of Pathology; 2000;
  9. Epstein JI, Allsbrook WC, Amin MB, Egevad LL. The 2005 International Society of Urological Pathology (ISUP) consensus conference on Gleason grading of prostatic carcinoma. Am J Surg Pathol. 2005;29:1228–1242
  10. Gleason DR, Mellinger GT The Veterans Administration Cooperative Urological Research Group. Prediction of prognosis for prostate adenocarcinoma by combined histological grading and clinical staging. J Urol. 1974;111:58–64
  11. Epstein JI, Herawi M. Prostate needle biopsies containing prostatic intraepithelial neoplasia or atypical foci suspicious for carcinoma: implications for patient care. J Urol. 2006;175:820–834
  12. Eichelberger LE, Cheng L. Does pT2b prostate cancer exist? Critical appraisal of the 2002 TNM classification of prostate cancer. Cancer. 2004;100:2573–2576
  13. Freedland SJ, Partin AW, Epstein JI, Walsh PC. Biochemical failure after radical prostatectomy in men with pathologic organ-confined prostate cancer: pT2 versus pT2b. Cancer. 2004;100:1646–1649
  14. Humphrey PA, Walther PJ. Adenocarcinoma of the prostate, I: simple sampling considerations. Am J Clin Pathol. 1993;99:746–759

PII: S0046-8177(07)00292-4

doi: 10.1016/j.humpath.2007.05.015

Human Pathology
Volume 38, Issue 9 , Pages 1305-1309.e4 , September 2007

Article Tools